Pharma Industry News Update, 3 January 2017
The World's Most Reputable Pharmaceutical Companies In 2016
Recently a survey was published scoring exactly how good people in developed countries all over the world feel about big pharma.
Be warned: 12% of respondents did not have knowledge or opinion about the companies’ overall performance. Meanwhile, 11% had no knowledge of companies’ citizenship activities (promoting good causes and protecting the environment) and 14% didn’t know anything about the workplaces of the firms they were asked to score.
More here...
Further Reading:
- Pharma Marketing Ethics & Corporate Reputation Compendium
- Can You Trust Patient Rankings of #Pharma Corporate Reputation?
- Americans Hate the #Pharma Industry Almost as Much as They Hate U.S. Gov't!
- Italian edition: Corporate Reputation of Pharma in 2015
- Pharma's Rep Among Patient Groups at 4-Year High
The Fault, Dear Pharma, is Not in SM ROI, But in Yourselves, That You Lack Commitment
According to blogger Richard Meyer, "while it does seem that some pharma companies are indeed starting to embrace social media, the biggest stumbling block seems to be that damn ROI bug which dictates everything that pharma marketers do."
Is it really proving ROI that prevents pharma marketers from using social media? Maybe not. First, how often do pharma marketers actually measure the ROI of their regular, non-social media campaigns? Probably never (listen to this podcast, for example, "You Want Marketing ROI? You're Not Ready to Measure ROI!") . Second, when the ROI of social media campaigns have been measured, most often it is positive (listen to this podcast audio snippet, for example, "A Successful, Integrated Mobile App Ad Campaign").
A more likely reason is lack of resources; i.e., money and personnel (FTEs), or commitment. For example, it would take a huge amount of resources to track down and correction misinformation about drugs on social media. The same is true for social media (read, for example, "Janssen to Shut Down Psoriasis 360 FaceBook Page Due to Lack of Commitment").
More here...
Further Reading:
- Do Privacy Concerns Stand in the Way of Measuring Pharma eMarketing ROI?
- The Causes Digital Marketing's Failure are Restricted Budgets & Inability to Measure ROI
Ousted FDA Official Explains Why New Drug Approvals Are the Lowest in Six Years
The reasons provided by the FDA’s director of the office of new drugs, Dr John Jenkins [who famously said the path taken by Sarepta to influence FDA to approve its Duchenne drug was "NOT a Good Model for Other Rare Drug Approvals" is soon to quit the FDA (read "Sarepta Critic Jenkins Thrown Under Bus as Janet Woodcock Takes Charge of FDA's Office of New Drugs"], were broken down into three points...
More here...
Further Reading:
- New Drugs Approved by FDA in 2016 is Half the Number Approved in 2015
- Over 700 Generics Were Approved by FDA in 2015 - A Record!